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A Label-Free Microfluidic Assay to quantitatively 
study antibiotic diffusion through lipid membranes 
J. Cama*a, C. Chimerel*a, S. Pagliaraa, A. Javera and U. F. Keysera   
With the rise in antibiotic resistance amongst pathogenic bacteria, the study of antibiotic 
activity and transport across cell membranes is gaining widespread importance. We present a 
novel, label-free microfluidic assay that quantifies the permeability coefficient of a broad 
spectrum fluoroquinolone antibiotic, norfloxacin, across lipid membranes using the UV 
autofluorescence of the drug. We use giant lipid vesicles as highly controlled model systems to 
study the diffusion through lipid membranes. Our technique directly determines the 
permeability coefficient without requiring the measurement of the partition coefficient of the 
antibiotic. 
 
 
 
 
 
 
Introduction 
Antibiotic resistance in bacteria has developed into one of the 
world’s foremost public health concerns1,2. The lack of new 
drugs combined with the rapid spread of resistant organisms 
poses a tremendous challenge for medical research and practice 
in the 21st century. Antibiotic resistance develops in a number 
of ways: the lipid membrane can act as a barrier preventing the 
accumulation of the drug in the cell, the drugs might be 
enzymatically decomposed, the drug targets can be modified; in 
many cases multiple mechanisms are active simultaneously3,4. 
A better understanding of drug transport across lipid 
membranes is highly desirable and could facilitate the 
development of the next generation of antibiotics.  
 
In our present drive towards miniaturisation and cost 
effectiveness in experimental science, microfluidics has 
emerged as a powerful tool. The small sample amounts 
required, high throughput capabilities and controlled 
microenvironments involved offer many advantages for the 
development of drug assays5,6,7,8,9,10. In this work, we develop a 
novel microfluidic technique to quantitatively examine the 
passive diffusion of antibiotics across lipid membranes. As a 
proof-of-principle, we study the passive diffusion of the broad 
spectrum fluoroquinolone antibiotic norfloxacin across vesicle 
lipid membranes using its autofluorescence11 in the UV. 
Norfloxacin targets the enzymes DNA gyrase and 
topoisomerase IV, disrupting DNA supercoiling and hence cell 
division12. Its accumulation within bacterial cells is therefore 
necessary for its antimicrobial activity. Previously, the 
accumulation of quinolones inside bacteria has been studied 
using radiolabelling13, bioassays14 and fluorimetry15, but it has 
been difficult to compare the published data due to differences 
in experimental conditions used16. These techniques do not 
separate the contributions to permeability from active and 
passive transport processes, and are further experimentally 
quite involved.  
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Figure 1a. Schematic of Optical Setup. Broadband white light is passed through a monochromator which selects the fluorescence excitation 
wavelength (340 nm). The excitation light is directed onto the microfluidic device and the emitted fluorescent radiation is focussed onto an 
EMCCD camera. Suction is applied at the outlet of the microfluidic network with a syringe pump. b. Schematic of microfluidic network. Lipid 
vesicles are exposed to a uniform concentration of the drug along the network. The t = 0 point is chosen after the drug has equilibrated 
across the channel width. Vesicles at t = 0 and later time points are observed in the same field of view. The two observation points are a 
length L apart along the network. As vesicles progress along the network, if the drug is permeable, the fluorescence intensity inside the 
vesicles increases.     
In our assay, we chose giant unilamellar vesicles as model 
systems, concentrating on passive transport in order to develop 
a better physical understanding of the interaction of the drug 
with a pure lipid membrane. It is estimated that between 80-
95% of commercial drugs are absorbed primarily by passive 
diffusion17,18, and thus an assay to quantify permeability 
coefficients due to passive diffusion would be of great interest 
to the pharmaceutical industry. It has previously been 
demonstrated that giant vesicles are stable in microfluidic 
flows, and show potential for membrane transport studies9. 
Furthermore, small (diameter ~ 180 nm), fixed vesicles 
containing a reporter complex have been used to study drug 
permeation in a microfluidic environment10. Our technique, 
however, is label-free; vesicles flow through channels 
containing norfloxacin in a microfluidic network such that they 
can be observed at different locations and compared 
simultaneously with vesicles in their initial state. Determination 
of the norfloxacin fluorescence within the vesicles as they 
accumulate the drug over time allows us to calculate the 
permeability coefficient of the drug directly in an effective and 
simple manner.  
 
 The experiment is fast, uses small volumes (~ 10 - 100 l) and 
can investigate individual vesicles in a label free manner. In 
contrast to traditional black lipid membrane techniques19, 
vesicles are more suitable cell mimics, and the advantage of 
using vesicles is that the same technique can then be adapted 
for cell use. This affords us the possibility of investigating 
active transport as well using suitable cell models. Furthermore, 
our assay directly evaluates the permeability coefficient without 
requiring information about the drug’s partition coefficient; 
fluoroquinolone partition coefficients reported in the literature 
vary over a large range14,20,21 leading to a wide range of 
permeability values. A direct measurement of drug permeability 
coefficients is therefore highly desirable.   
 
Experimental details 
Materials and methods 
Unless otherwise stated, all lenses and mirrors were obtained 
from Thorlabs UK and all chemicals from Sigma Aldrich UK. 
 
Optical Setup 
 
The optical setup is a custom built UV epifluorescence 
microscope described schematically in Figure 1a. The output 
from a broadband white light source (EQ99FC, Energetiq, 
USA) is passed to a monochromator (Monoscan 2000, 
OceanOptics) whereupon we select the desired excitation 
wavelength (340 nm) and direct it onto the microfluidic device 
via a Köhler illumination pathway and a suitable dichroic 
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mirror (DLHS UV 351-355, Qi-Optiq, Germany). The objective 
used is a 60× water immersion UPLSAPO Olympus objective 
(NA 1.2). The emitted fluorescent light passes through the 
dichroic and is focussed onto the detector, an EMCCD camera 
(Evolve 512, Photometrics – exposure time 2 ms, bin 2, EM 
gain 100, frame rate 65 fps) via a tube lens and a mirror. All 
lenses used (apart from the objective) are made from UV fused 
silica to optimise UV transmission and the optical fibers are UV 
grade (OceanOptics). The camera is controlled using the open-
source software Manager 1.422. 
 
Microfluidic Chip Design and Fabrication 
 
The microfluidic chip (schematic - Figure 1b) was constructed 
using standard photo- and soft lithography techniques23,24. The 
mask was designed in AutoCAD and printed on emulsion film 
(JD Photo-Tools UK). The design is attached in the electronic 
supplementary materials. SU8 3050 (Chestech UK) photoresist 
was spin coated (SCS Spincoat G3P-8, 7s at 500 rpm followed 
by 30s at 3,000 rpm) onto a Si wafer (Microchemicals, 
Germany) and then baked on a hot plate (96 0C for 20 mins). 
After aligning the film mask on the wafer, it was exposed to 
UV (the UV lamp was an OAI system with an output power of 
200 W) for 15 seconds, post-baked for 6-7 mins at 96 0C and 
then developed in Propylene glycol monomethyl ether acetate 
(PGMEA) for approximately 10 mins. This was then rinsed 
with isopropanol and blow dried with N2. A negative replica of 
the mold was obtained using Sylgard 184 Polydimethylsiloxane 
(PDMS- from Dow Corning); a 9:1 ratio of elastomer:curing 
agent PDMS mixture was poured onto the Si mold and cured 
for 55 mins at 60 0C in an oven. The fabricated device (Figure 
1b) has a network of microfluidic channels that are 40 m wide 
and 50 m high; the total length of the network from the T 
junction to the outlet reservoir is approximately 380 mm. There 
is also a network of filter pillars in the inlet reservoirs to 
prevent lipid aggregates from entering the microfluidic network 
and blocking the flow. Finally, the PDMS chip was bonded to a 
glass coverslip (Type 1, Assistent, Germany) by exposing the 
surfaces being bonded to an Oxygen plasma (10 W plasma 
power, 10 s exposure, 25 sccm, plasma etcher from Diener, 
Royal Oak, MI) and then binding the two exposed surfaces 
together to create a sealed microfluidic device. This was placed 
in an oven at 60 0C for 10 mins to enhance the adhesion. 
 
 
Formation of Giant Unilamellar Vesicles 
 
Giant unilamellar vesicles (GUVs) were created by 
electroformation using a Nanion Vesicle Prep Pro setup. 60 l 
of 5 mg/ml 1,2-diphytanoyl-sn-glycero-3-phosphocholine 
(DPhPC) lipid (Avanti Polar Lipids) in chloroform was spread 
on the conducting surface of an Indium Tin Oxide (ITO) coated 
glass slide (Nanion/Visiontek) within a rubber O-ring. The 
chloroform was evaporated for 10 mins in a desiccator 
following which 600 l of the appropriate buffer (200 mM 
Sucrose in a 5 mM Phosphate Buffer for pH 7 or 200 mM 
Sucrose in a 5 mM acetic acid buffer for pH 5) was deposited 
within the O-ring and a sandwich made with another ITO 
coated slide (conducting surfaces facing each other). This was 
placed in the Nanion Vesicle Prep Pro whereupon 
electroformation proceeds in 3 steps: (i) The a/c voltage 
increases linearly from 0 to 3 V peak to peak (p-p) at 5 Hz in 5 
mins. (ii) The voltage stays at 3 V p-p and 5 Hz for 2 hrs. (iii) 
The voltage decreases linearly to 0 V at 5 Hz in 5 mins. The 
electroformation was carried out at 37.5 0C.  The vesicles were 
stored at 4 0C and used within a week. 
 
Microfluidic flow control 
 
The microfluidic flows were controlled by applying suction at 
the outlet reservoir using a neMESYS syringe pump system 
with a 1 ml Duran Borosilicate glass syringe (ILS, Germany). 
The tubing used was Upchurch 1520G (0.03 inch inner 
diameter). At the inlets, pipette tips with 50 l of vesicle stock 
solution and 50 l of 2 mM norfloxacin solution respectively 
were input into the two reservoirs, using a previously described 
technique25. Initially, to ensure a uniform distribution of 
norfloxacin throughout the network, a fast flow was applied 
(approx. 200 l/hr flow rate). Once the fluorescence intensities 
were observed to be uniform in the detection regions, the flow 
rate was decreased to about 5-10 l/hr. Data collection was 
started once the flows settled and individual vesicles were slow 
enough (~0.8 mm/s) to be tracked in the field of view (120 m 
across) for about 5-10 frames to ensure a reliable statistical 
analysis of the relevant measured quantities. It is important to 
note that we study individual vesicles as they pass through the 
network– this is not a bulk experiment – with a throughput up 
to 100 vesicles per hour. 
 
Data Analysis 
 
We determined normalised fluorescence intensity differences 
between the exterior and interior of the vesicles at t = 0 (I1) 
and later at tf (I2): 
∆𝑰𝟏 =  
𝑰𝒐𝒖𝒕 − 𝑰𝟏
𝑰𝒐𝒖𝒕
       (𝒕 =  𝟎) 
∆𝑰𝟐 =  
𝑰𝒐𝒖𝒕 − 𝑰𝟐
𝑰𝒐𝒖𝒕
       (𝒕 =  𝒕𝒇) 
I1 and I2 refer to the average internal fluorescence intensities 
measured around the centre of the vesicles at times t = 0 and t 
= tf and Iout refers to the fluorescence intensity outside the 
vesicle, which remains constant. After solving the diffusion 
equation (for full details of the theoretical model and MATLAB 
image analysis see supplementary information), we obtained 
the following equation that was used for analysis:  
𝒍𝒏( ∆𝑰𝟐 − ∆𝑰𝟏 + 𝟏 ) =  −𝟑
𝑷𝒕
𝑹
                   (1) 
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where P is the permeability coefficient, R the vesicle radius and 
t the time taken to travel from the initial to the final vesicle 
detection point. 
 
Results and discussion  
The final microfluidic chip design is the result of a number of 
preliminary investigations. Preliminary single vesicle 
experiments implied that the time scale of norfloxacin diffusion 
through vesicle membranes was on the order of minutes at pH 
7. Furthermore, microfluidics experiments revealed a vesicle 
speed of around 0.8-1 mm/s to be the optimum for detection in 
our system, as mentioned above. Based on these considerations, 
we designed a network of microfluidic channels which the 
vesicles would take around 5-6 minutes to traverse. At these 
flow speeds, our preliminary experiments indicated that the 
norfloxacin mixes across the entire channel width within a 
couple of millimetres’ distance from the T junction. In order to 
ensure that this was the case at the initial t = 0 detection point in 
our system, we chose the length to this point (from the T 
junction) to be significantly longer (~20 mm) in the final 
design.    
 
To assess the diffusion through the membrane, we measure the 
intensity within the vesicles at different points in the chip. 
Figure 2 shows data for vesicles at pH 5 and pH 7. The 
microscopy images show vesicles (dark) in the microfluidic 
channels at different points, surrounded by the autofluorescing 
norfloxacin. Data is shown for two lengths travelled, L = 45.5 
mm and L = 182 mm; data for other lengths is presented in the 
supplementary information. From the images it is clear that 
vesicles at pH 5 remain dark as they travel through the network, 
whereas at pH 7 they become progressively brighter. Thus the 
autofluorescing norfloxacin permeates the membrane at pH 7 
far more readily than at pH 5. This effect is further apparent in 
the plots in Figure 2. At pH 7 (red circles), as the length 
travelled increases, Iin increases and there is a corresponding 
decrease in I. Almost no significant change is observed at pH 
5 (green triangles). The radial dependence of I at t = 0 (black 
squares) occurs since our measurements are in brightfield rather 
than confocal mode; at later times, the radial dependence is 
both due to this effect as well as due to drug diffusion. This is 
addressed in our analysis.     
 
Figure 3 shows three different techniques used to analyse the 
data and determine the permeability coefficient of norfloxacin. 
The equation atop Figure 3a can be extracted from the 
theoretical analysis (supplementary information). Since the 
process being studied is diffusion, we expect to see an 
exponential dependence of Iin on time (and hence length L). 
This analysis requires values of vesicle velocity and radius, for 
which the average velocity (0.81 ± 0.01 mm/s) and average 
radius (13.6 ± 0.1 m) measured (pH 7) were used. Using these 
and the data from the exponential fit, we obtain a permeability 
coefficient (pH 7) of P = 5.2 ± 0.4×10-7 cm/s.  
 
Furthermore, since we determine the flow speed for each 
vesicle, we can calculate the time taken by each vesicle to 
travel the length L from the initial to the final detection point. 
Collating this with our measurements of I and the radius of 
each vesicle (an average of the semi-major and semi-minor 
axes), we know all the parameters required to determine the 
permeability coefficients for each vesicle detected using 
equation (1). Histograms of these values for the pH 7 
experiments are shown in Figure 3c. The average permeability 
coefficient determined is P = 5.9 ± 0.2×10-7 cm/s (N = 272). 
Finally, we can use the same equation (1) to determine the 
permeability coefficient (pH 7) from the slope of Figure 3b. 
This gives P = 6.6 ± 0.6×10-7 cm/s. The difference in value 
between the average (Figure 3c) and the slope (Figure 3b) can 
be attributed to the standard linear regression (least squares) 
Figure 2. Norfloxacin diffusion into single lipid vesicles. Images of 
autofluorescent norfloxacin diffusing into vesicles (ex = 340 nm) at 
pH 5 (left) and pH 7 (right). L is the length travelled from the initial 
(t = 0) to the final (t = tf) vesicle detection point. It is evident that 
there is an increase in the fluorescence intensities inside the vesicles 
(Iin) at pH 7, and a corresponding decrease in I. The decrease in I 
is proportional to the length (L) travelled, as seen in the plots (the 
difference between the black and red points becomes larger as L 
increases). At pH 5, the decrease in I is much less apparent (the 
green and black points overlap) and Iin shows a much smaller 
increase within the timescales measured. It is thus clear that the 
permeability of norfloxacin through the lipid bilayer is much higher 
at pH 7 than at pH 5. The scale bar is 10 m (in all images). Each 
data point in the plots represents a measurement on an individual 
vesicle. The radial dependence in the plots is discussed in the text 
and in further detail in the supplementary information.  
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technique employed in determining the slope. All errors 
reported are standard errors of the mean. Thus there is good 
agreement using all three analysis techniques.  
 
At pH 5, the majority of the norfloxacin molecules are 
positively charged, but at pH 7 a significant proportion of the 
molecules exist in their uncharged form20. As indicated in the 
plots in Figure 2 and from Figure 3a, it is clear that at pH 5 
fewer norfloxacin molecules permeate the membrane. This is as 
expected, since polar charged molecules have a low affinity for 
the non-polar core of the bilayer. From our data we estimate a 
permeability coefficient of 0.5-1.5 × 10-7 cm/s at pH 5, a 6-fold 
decrease as compared to pH 7. This also confirms that our 
vesicles are indeed a stable model system not susceptible to 
leakage.  
With fluoroquinolones there is significant discrepancy among 
the published values of apparent partition coefficients, and 
hence in the predicted permeability coefficients16. Apparent 
partition coefficients for norfloxacin have been reported as 0 
(pH 7)21, 0.003 (pH 7.2)20 and 0.01 (pH 7.2)14, which would 
imply a permeability coefficient ranging from 0 to around 10-5 
cm/s. Our method does not require knowledge of the partition 
coefficient; we provide a direct measurement of the 
permeability coefficient, and the values we obtain are well 
within the range predicted in the literature20. 
  
We thus have a new and direct technique of measuring the 
permeability coefficient of drugs passively diffusing across 
lipid membranes. In contrast to previously described methods, 
we do not require any labelling or chemical complex formation 
in order to track the drug molecules. We further do not need to 
determine the drug partition coefficients in artificial aqueous-
organic phase systems; we directly obtain the permeability 
coefficient across the membrane of interest, which is the 
quantity required when designing and testing new drugs.  
 
At present the experiment throughput is limited primarily by 
the camera speed, since faster flows (vesicle speeds > 1.5 
mm/s) lead to a blurring of the vesicles in the images. The 
throughput could be increased by using higher flow rates with a 
faster camera, enabling the detection of a larger number of 
vesicles in a shorter period of time.  
 
Our technique paves the way to assess antibiotic diffusion in 
different vesicle compositions, including proteo-liposomes 
containing membrane channels (such as OmpF26) implicated in 
antibiotics transport. Scaling down the microfluidic channel 
dimensions should even allow the examination of individual 
bacteria and a similar assay could be used to quantify the 
permeability of drugs in resistant and normal pathogens.  
 
This label-free technique is directly applicable when the drug or 
molecule being studied is autofluorescent. Many interesting 
biomolecules and drugs are indeed autofluorescent, especially 
in the UV, and thus give this assay a wide applicability. 
However, if the molecule of interest is not autofluorescent, one 
would have to tailor the experiment to suit the study, for 
example by using reporter complexes within the vesicles that 
fluoresce in the presence of the drug, as demonstrated in 
reference [10]. 
 
Membrane permeation across artificial and cell membranes has 
been extensively studied in microfluidic platforms9,10,27-31. 
However, most of the work has concentrated on developing 
platforms for supported lipid bilayers in microfluidic chambers. 
As discussed in the Introduction, lipid vesicles are 
geometrically much better cell mimics, and techniques for 
studying permeation across vesicle membranes can directly be 
adapted to studying permeation into living cells. Work has 
previously been done on using vesicles in microfluidic 
platforms to study membrane permeation9,10, but the techniques 
Figure 3. Measurements of the permeability coefficient (P). a. 
Dependence of Iin/Iout with respect to the length L travelled by 
vesicles from the initial to the final detection point. The solid lines 
are fits based on our theoretical expectation of a diffusive process 
governing the transport of norfloxacin across lipid membranes. 
Error bars represent standard errors of the mean. From the fit, we 
have extracted P=5.2±0.4×10-7 cm/s at pH 7. b. Dependence of 
parameter A (defined in the figure) on 1/R. The slope of the linear fit 
gives us another technique of determining P. The value obtained 
(pH 7) was P=6.6±0.6×10-7 cm/s. c. Histogram of P values for 
individual vesicles. Values determined using equation (1). The 
average value of these single vesicle calculations gives 
P=5.9±0.2×10-7 cm/s (N = 272).  
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involved fixing or trapping vesicles, which will limit 
throughput. Our assay involves analysing flowing vesicles in 
free solution, and is thus capable of much higher throughput. 
Furthermore, the microfluidic chip fabrication techniques 
involved are simpler, since structures or chemical modifications 
for vesicle trapping are not required. We trust that these 
simplifications make our assay accessible and useful to not only 
the microfluidics community, but also to scientists involved in 
drug development and biologists interested in permeation 
studies on the single cell level. 
Conclusions 
We have described a novel, label-free technique of studying 
passive drug transport across lipid membranes that directly 
determines drug permeability coefficients using lipid vesicles. 
It is experimentally simple and can be adapted for cell work. 
The experiment itself is robust and can be run for hours at a 
stretch. As a proof-of-principle, we have used it to determine 
the permeability coefficient of the antibiotic norfloxacin across 
DPhPC lipid membranes at pH 7, and have validated 
predictions for the effect of pH on norfloxacin permeability.  
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